REMS Need To Be More Easily Modified, Attorney Says; Prior Approval Supplements Too Cumbersome
Executive Summary
FDA could facilitate improvements to Risk Evaluation and Mitigation Strategies by giving companies some discretion to modify REMS elements, according to Hogan and Hartson partner Meredith Manning
You may also be interested in...
REMS Assessments Need Very Recent Data, FDA Draft Guidance Says
Sponsors conducting assessments of a product's Risk Evaluation and Mitigation Strategy will need to complete them within 60 days of collecting the last piece of data, according to a draft FDA guidance
REMS Assessments Need Very Recent Data, FDA Draft Guidance Says
Sponsors conducting assessments of a product's Risk Evaluation and Mitigation Strategy will need to complete them within 60 days of collecting the last piece of data, according to a draft FDA guidance
Will REMS Delay Generics? Revlimid Petition May Help Determine The Answer
Dr. Reddy’s asks FDA to spell out policy to assure that new Risk Evaluation and Mitigation Strategies will be used to block generics. Celgene’s refusal to make Revlimid available for bioequivalence study is at issue.